 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
AntiVirals is a pioneer company in the field of gene-inactivating technology referred to as antisense and has developed a patented class of antisense compounds which may be useful in the treatment of a wide range of human diseases. The Company also has developed new drug delivery technology which may be useful with many FDA- approved drugs as well as with its antisense compounds. The Company's drug development program has two areas of near term focus: * NEU-GENE antisense compounds for selected applications, and * CYTOPORTER drug delivery engines for enhanced delivery of FDA-approved drugs with delivery problems. The Company's long term product development program combines its NEU-GENE and CYTOPORTER technologies to produce combination drugs with potential applications for many human diseases. The Company has been issued 20 PATENTS!!! and several patent applications covering the basic compositions of matter, methods of synthesis, and medical uses of NEU-GENE and CYTOPORTER compounds. Antisense technology has the potential to provide safe and effective treatment for a broad range of diseases that previously have been difficult to address, including viral and host diseases such as cancer, AIDS, herpes etc. The Company's new approach uses synthetic molecules designed to inactivate selected genetic sequenses that underlie the disease process and thereby halt the disease. To reach their therapeutic targets, many drugs must cross tissue and cellular barriers. Drugs that have an intaceelular site of action must cross the lipid (fat like) barrier of cellular membranes to move from the aqueous environment of the blood into the interior of target cells. Therefore these drugs must achieve solubility in both water and lipids. Since few compounds have these solubility characteristics, many drug canidates are a compromise between inherant solubility and effective delivery. This trade off reduces efficacy and may significantly heighten toxicity of many drug canidates, as well as many FDA- approved drugs. * Dr. Dennis Burger: Founder and CEO Co-founder of Epitope from 1981-1990 which went public in 1987 at $5.00 with splits its around $70.00 one of the most succesful bio-tech stocks out of the Pacific northwest in the last decade. Dr. Burger is also on the board of directors for Celegy, Supergen, and Trinity. *Dr. Joseph Rubinfeld: Director Co-founder of Aamgen in 1980 the most succesful bio-tech stock in the last 10 years. Also was Vice president and director of research and development at Bristol Myers. I anticipate at least four marketing agreements in place, possibly by the end of the year with very large pharmecutical companies. Also the average market cap. for these companies is about 4x higher than current. Buy and watch it go!!!! JMO IGUANA | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |